An Exposure‐Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4 β β ‐Hydroxycholesterol in Healthy Subjects

摘要

Abstract The objectives of this analysis were to establish the exposure‐response relationship between plasma rifampicin and 4β‐hydroxycholesterol (4βHC) concentration and to estimate the effect of weak, moderate, and potent CYP3A induction. Plasma rifampicin and 4βHC concentration‐time data from a drug‐drug interaction study with rifampicin 600 mg were used for model development. An indirect response model with an effect compartment described the relationship between rifampicin and 4βHC concentrations. The model predicted that the equilibration t 1/2 and 4βHC t 1/2 were 72.8 and 142 hours, respectively. EM 50 and E max of rifampicin induction were 32.6 μg and 8.39‐fold, respectively. The population PK‐PD model was then used to simulate the effects of rifampicin 10, 20, and 100 mg on plasma 4βHC for up to 21 days, in which rifampicin 10, 20, and 100 mg were used to represent weak, moderate, and strong inducers, respectively. The model‐predicted median (5th, 95th percentiles) 1.13 (1.04, 1.44)‐, 1.28 (1.10, 1.71)‐, and 2.10 (1.45, 3.49)‐fold increases in plasma 4βHC after 14‐day treatment with rifampicin 10, 20, and 100 mg, respectively. A new drug candidate can likely be classified as a weak, moderate, or strong inducer if baseline‐normalized plasma 4βHC increases by 1.13‐, 1.13‐ to 2.10‐, or 2.10‐fold, respectively, after 14 days of dosing.